ACM
AVIR icon

Aquatic Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Aquatic Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,700
Closed -$37K – 1255
2022
Q4 		$37K Buy
+7,700
New +$39K ﹤0.01% 1065

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aquatic Capital Management's AVIR Position: Q1 2023 in Review

Aquatic Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2023, closing a stake of 7,700 shares — an estimated $37K sold.

Aquatic Capital Management first reported a position in AVIR in Q4 2022 and held it in 1 quarter. The position peaked at $37K in Q4 2022. 130 funds tracked by Wall St. Rank hold AVIR as of Q1 2023.

  • Aquatic Capital Management reported no remaining Atea Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Aquatic Capital Management sold 7,700 Atea Pharmaceuticals shares in Q1 2023, an estimated $37K.
  • Aquatic Capital Management first reported a position in Atea Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Aquatic Capital Management's Atea Pharmaceuticals position peaked at $37K in Q4 2022.
  • 130 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2023.

Based on Aquatic Capital Management's 13F filing for Q1 2023, filed 15 May 2023.